Ruiyan Wu

1.7k total citations · 1 hit paper
24 papers, 1.0k citations indexed

About

Ruiyan Wu is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Ruiyan Wu has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in Ruiyan Wu's work include Colorectal Cancer Treatments and Studies (8 papers), Colorectal Cancer Surgical Treatments (8 papers) and Colorectal and Anal Carcinomas (8 papers). Ruiyan Wu is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Colorectal Cancer Surgical Treatments (8 papers) and Colorectal and Anal Carcinomas (8 papers). Ruiyan Wu collaborates with scholars based in China and United States. Ruiyan Wu's co-authors include Ting Sun, Liang Ming, Xuan Li, Rong Deng, Gong‐Kan Feng, Jia Mai, Xiao‐Feng Zhu, Yuhong Chen, Hai‐Liang Zhang and Lin Jiao and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Ruiyan Wu

21 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The role of m6A RNA methylation in cancer

2019 662 citations Ting Sun, Ruiyan Wu et al. Biomedicine & Pharmacotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruiyan Wu China	10	817	437	210	121	96	24	1.0k
Lu Zang China	12	716 0.9×	448 1.0×	216 1.0×	111 0.9×	69 0.7×	26	923
R. Tang Taiwan	12	752 0.9×	468 1.1×	345 1.6×	74 0.6×	126 1.3×	14	1.1k
Ben Yue China	9	1.1k 1.3×	951 2.2×	110 0.5×	56 0.5×	78 0.8×	14	1.2k
Jinfeng Ning China	13	559 0.7×	313 0.7×	121 0.6×	135 1.1×	75 0.8×	22	724
Xing Feng China	13	823 1.0×	337 0.8×	129 0.6×	69 0.6×	77 0.8×	29	1.0k
Yufan Ying China	18	810 1.0×	474 1.1×	107 0.5×	139 1.1×	89 0.9×	30	953
Wen Ni China	12	884 1.1×	730 1.7×	154 0.7×	83 0.7×	78 0.8×	18	1.2k
Haiyun Xie China	20	953 1.2×	575 1.3×	97 0.5×	101 0.8×	90 0.9×	31	1.1k
Huafu Li China	10	401 0.5×	252 0.6×	110 0.5×	104 0.9×	57 0.6×	18	595
Xueyou Ma China	15	498 0.6×	262 0.6×	83 0.4×	176 1.5×	69 0.7×	29	687

Countries citing papers authored by Ruiyan Wu

Since Specialization

Citations

This map shows the geographic impact of Ruiyan Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruiyan Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruiyan Wu more than expected).

Fields of papers citing papers by Ruiyan Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruiyan Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruiyan Wu. The network helps show where Ruiyan Wu may publish in the future.

Co-authorship network of co-authors of Ruiyan Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruiyan Wu. A scholar is included among the top collaborators of Ruiyan Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruiyan Wu. Ruiyan Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Chen, et al.. (2025). Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives. Molecular Cancer. 24(1). 131–131. 10 indexed citations

Wu, Ruiyan, Juefeng Wan, Hui Zhang, et al.. (2025). Total neoadjuvant therapy in high-risk rectal cancer: organ preservation and survival outcomes in a single-center retrospective cohort. Therapeutic Advances in Medical Oncology. 17. 22777202–22777202.

Huang, Lili, Ruiyan Wu, Yida Li, et al.. (2025). Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. Cell Reports Medicine. 6(8). 102251–102251. 2 indexed citations

Chen, Y., Zhiyuan Zhang, Hui Zhang, et al.. (2024). Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE).. Journal of Clinical Oncology. 42(16_suppl). e15570–e15570.

Wan, Juefeng, Ruiyan Wu, Lijun Shen, et al.. (2023). TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial. Frontiers in Oncology. 13. 1304767–1304767. 2 indexed citations

Zhang, Lijie, Minghe Wang, Jing Zhang, et al.. (2023). Long-term outcomes in a retrospective cohort of patients with rectal cancer with complete response after total neoadjuvant therapy: a propensity-score weighted analysis. Therapeutic Advances in Medical Oncology. 15. 2642691–2642691. 3 indexed citations

Zhou, Shujuan, Chenchen Wang, Lijun Shen, et al.. (2023). Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT). Frontiers in Oncology. 13. 1274487–1274487. 4 indexed citations

Chen, Y., Yaqi Wang, Hui Zhang, et al.. (2023). Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E). BMJ Open. 13(10). e076048–e076048. 1 indexed citations

Wu, Ruiyan, Bi‐Cheng Wang, Kun Wang, et al.. (2023). Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis. Frontiers in Oncology. 12. 994276–994276. 1 indexed citations

10.

Wang, Yaqi, Lijun Shen, Juefeng Wan, et al.. (2022). Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation. Frontiers in Immunology. 13. 1067036–1067036. 28 indexed citations

11.

Wang, Yaqi, Lijun Shen, Juefeng Wan, et al.. (2022). Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH). BMC Cancer. 22(1). 274–274. 30 indexed citations

12.

Wang, Yaqi, Lijun Shen, Juefeng Wan, et al.. (2022). Short-course radiotherapy combined with CAPOX and toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: Preliminary findings from a randomized, prospective, multicenter, double-arm, phase II trial (TORCH).. Journal of Clinical Oncology. 40(16_suppl). e15602–e15602. 4 indexed citations

13.

Chen, Hui, Xiaolin Ge, Zhao‐Yue Zhang, et al.. (2021). M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma. Translational Lung Cancer Research. 10(5). 2172–2192. 26 indexed citations

14.

Wang, Boyan, Yongjie Zhou, Min Jia, et al.. (2021). Choice of Treatment for Patients With Non–small-cell Lung Cancer >5 cm Between Surgery Alone and Surgery Plus Adjuvant Radiotherapy. Frontiers in Surgery. 8. 649802–649802.

15.

Sun, Ting, Ruiyan Wu, & Liang Ming. (2019). The role of m6A RNA methylation in cancer. Biomedicine & Pharmacotherapy. 112. 108613–108613. 662 indexed citations breakdown →

16.

Zhu, Ying‐Hui, Ruiyan Wu, Yan Yu, et al.. (2019). Clinical significance and function of RDH16 as a tumor‐suppressing gene in hepatocellular carcinoma. Hepatology Research. 50(1). 110–120. 14 indexed citations

17.

Kong, Pengfei, Ruiyan Wu, Wenzhuo He, et al.. (2017). Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis. Journal of Cancer. 8(16). 3296–3308. 4 indexed citations

18.

Kong, Pengfei, Ruiyan Wu, Chenlu Yang, et al.. (2016). Prognostic Impact of the Signet Ring Cell Type in Node-Negative Gastric Cancer. Scientific Reports. 6(1). 26313–26313. 14 indexed citations

19.

Kong, Pengfei, Ruiyan Wu, Xuechao Liu, et al.. (2016). The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis. Journal of Cancer. 7(15). 2247–2257. 28 indexed citations

20.

Zhong, Qiong, et al.. (2016). Association of ADH1B Arg47His and ALDH2 Glu487Lys polymorphisms with risk of colorectal cancer and their interaction with environmental factors in a Chinese population. Genetics and Molecular Research. 15(3). 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact